

## General Assembly

## Raised Bill No. 352

February Session, 2004

LCO No. 1525

\*01525\_\_\_\_\_PH\_\*

Referred to Committee on Public Health

Introduced by: (PH)

## AN ACT CONCERNING THE PREFERRED DRUG LIST.

Be it enacted by the Senate and House of Representatives in General Assembly convened:

- 1 Section 1. Section 17b-274d of the general statutes, as amended by
- section 19 of public act 03-2, section 63 of public act 03-278 and section
- 3 83 of public act 03-3 of the June 30 special session, is repealed and the
- 4 following is substituted in lieu thereof (Effective October 1, 2004):
- 5 (a) Pursuant to 42 USC 1396r-8, there is established a Medicaid
- 6 Pharmaceutical and Therapeutics Committee within the Department of
- 7 Social Services. Said committee shall convene on or before March 31,
- 8 2003.
- 9 (b) The Medicaid Pharmaceutical and Therapeutics Committee shall
- 10 be comprised as specified in 42 USC 1396r-8 and shall consist of
- 11 [fourteen members appointed by the Governor.] twenty members.
- 12 Fourteen members shall be appointed by the Governor as follows: Five
- 13 members shall be physicians licensed pursuant to chapter 370,
- 14 including one general practitioner, one pediatrician, one geriatrician,
- one psychiatrist and one specialist in family planning; [,] four members
- shall be pharmacists licensed pursuant to chapter 400j; [,] two

- 17 members shall be visiting nurses, one specializing in adult care and 18 one specializing in psychiatric care; [,] one member shall be a clinician 19 designated by the Commissioner of Mental Health and Addiction 20 Services; [,] one member shall be a representative of pharmaceutical 21 manufacturers and one member shall be a consumer representative. 22 Two members shall be appointed by the president pro tempore of the 23 Senate, two members shall be appointed by the speaker of the House 24 of Representatives, one member shall be appointed by the minority 25 leader of the Senate and one member shall be appointed by the 26 minority leader of the House of Representatives. The committee may, 27 on an ad hoc basis, seek the participation of other state agencies or 28 other interested parties in its deliberations. The members shall serve 29 for terms of two years from the date of their appointment. Members 30 may be appointed to more than one term. The Commissioner of Social 31 Services, or the commissioner's designee, shall convene the committee 32 following the [Governor's] designation of appointments. The 33 administrative staff of the Department of Social Services shall serve as 34 staff for said committee and assist with all ministerial duties. The 35 Governor shall ensure that the committee membership includes 36 Medicaid participating physicians and pharmacists, with experience 37 serving all segments of the Medicaid population.
- 38 (c) Committee members shall select a chairperson and vice-39 chairperson from the committee membership on an annual basis.
- (d) The committee shall meet at least quarterly, and may meet at other times at the discretion of the chairperson and committee membership. The committee shall comply with all regulations adopted by the department, including notice of any meeting of the committee, pursuant to the requirements of chapter 54.
  - (e) On or before July 1, 2003, the Department of Social Services, in consultation with the Medicaid and Pharmaceutical Therapeutics Committee, shall adopt a preferred drug list for use in the Medicaid and ConnPACE programs. To the extent feasible, the department shall

45 46

47

48

- (f) Except for mental-health-related drugs and antiretroviral drugs, reimbursement for a drug not included in the preferred drug list is subject to prior authorization.
- (g) The Department of Social Services shall publish and disseminatethe preferred drug list to all Medicaid providers in the state.
  - committee shall ensure that the pharmaceutical manufacturers agreeing to provide a supplemental rebate pursuant to 42 USC 1396r-8(c) have an opportunity to present evidence supporting inclusion of a product on the preferred drug list unless a court of competent jurisdiction, in a final decision, determines that the Secretary of Health and Human Services does not have authority to allow such supplemental rebates, provided the inability to utilize supplemental rebates pursuant to this subsection shall not impair the committee's authority to maintain a preferred drug list. Upon timely notice, the department shall ensure that any drug that has been approved, or had any of its particular uses approved, by the United States Food and Drug Administration under a priority review classification, will be reviewed by the Medicaid Pharmaceutical and Therapeutics Committee at the next regularly scheduled meeting. To the extent feasible, upon notice by a pharmaceutical manufacturer, the department shall also schedule a product review for any new product

60

61

62

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

- 81 at the next regularly scheduled meeting of the Medicaid
- 82 Pharmaceutical and Therapeutics Committee.
- 83 (i) Factors considered by the department and the Medicaid 84 Pharmaceutical and Therapeutics Committee in developing the 85 preferred drug list shall include, but not be limited to, clinical efficacy,
- 86 safety and cost effectiveness of a product.
- (j) The Medicaid Pharmaceutical and Therapeutics Committee may also make recommendations to the department regarding the prior authorization of any prescribed drug covered by Medicaid in accordance with the plan developed and implemented pursuant to section 17b-491a.
- 92 (k) Medicaid recipients may appeal any department preferred drug 93 list determinations utilizing the Medicaid fair hearing process 94 administered by the Department of Social Services established 95 pursuant to chapter 54.
- 96 (l) The provisions of this section shall apply to the state-97 administered general assistance program.

This act sha	ll take effect as follows:
Section 1	October 1, 2004

## Statement of Purpose:

To require the development of a comprehensive preferred drug list, rather than one limited to three classes of drugs.

[Proposed deletions are enclosed in brackets. Proposed additions are indicated by underline, except that when the entire text of a bill or resolution or a section of a bill or resolution is new, it is not underlined.]